Schilddrüsenkarzinome betreffen vor allem (95%) die folikulären Zellen, die für die Sekretion des Schilddrüsenhormons zuständig sind. Der Rest entwickelt sich aus parafolikulären, medullären Zellen, die das Calcitonin produzieren. Mutationen können als Keimbahn- oder somatische Mutationen vorkommen.
1. |
Xing M et al. (2004) Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. |
2. |
Chua EL et al. (2000) Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. |
3. |
Corvi R et al. (2000) RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma. |
4. |
Klein M et al. (2001) Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. |
5. |
Hrafnkelsson J et al. (2001) Familial non-medullary thyroid cancer in Iceland. |
6. |
Elisei R et al. (2001) RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. |
7. |
Kitamura Y et al. (2001) Allelotyping of follicular thyroid carcinoma: frequent allelic losses in chromosome arms 7q, 11p, and 22q. |
8. |
Mechler C et al. (2001) Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. |
9. |
Savagner F et al. (2002) Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients. |
10. |
Carlomagno F et al. (2002) The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. |
11. |
Finn SP et al. (2003) Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. |
12. |
Baudin E et al. (2003) Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. |
13. |
Kimura ET et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. |
14. |
Carlomagno F et al. (2003) Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). |
15. |
Namba H et al. (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. |
16. |
Fenton CL et al. (2000) The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. |
17. |
Weber F et al. (2005) Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. |
18. |
Ciampi R et al. (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. |
19. |
Wagner K et al. (2005) Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: diagnostic synergy for detecting thyroid cancer. |
20. |
Sarquis MS et al. (2006) High frequency of loss of heterozygosity in imprinted, compared with nonimprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas. |
21. |
García-Rostán G et al. (2005) Mutation of the PIK3CA gene in anaplastic thyroid cancer. |
22. |
Zhu Z et al. (2006) Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. |
24. |
Abubaker J et al. (2008) Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. |
26. |
Gudmundsson J et al. (2009) Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. |
27. |
Vriens MR et al. (2009) Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. |
28. |
Takahashi M et al. (2010) The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. |
29. |
Bonora E et al. (2010) Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. |
30. |
Jendrzejewski J et al. (2012) The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. |
31. |
Maio M et al. (2003) Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. |
32. |
Loré F et al. (2000) Unilateral renal agenesis in a family with medullary thyroid carcinoma. |
33. |
Cote GJ et al. (2003) Lessons learned from the management of a rare genetic cancer. |
34. |
Klugbauer S et al. (1998) Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. |
35. |
Klugbauer S et al. (1999) The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. |
36. |
Nikiforova MN et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. |
37. |
Dwight T et al. (2003) Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. |
38. |
Kroll TG et al. (2000) PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. |
39. |
Gimm O et al. (1999) Mutation analysis reveals novel sequence variants in NTRK1 in sporadic human medullary thyroid carcinoma. |
40. |
Ngan ES et al. (2009) A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. |
41. |
Fortunati N et al. (2004) Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. |
42. |
Lairmore TC et al. (1991) Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A. |
43. |
Ferrer JP et al. (1991) Primary localized cutaneous amyloidosis and familial medullary thyroid carcinoma. |
44. |
Narod SA et al. (1989) Linkage analysis of hereditary thyroid carcinoma with and without pheochromocytoma. |
45. |
Loré F et al. (2001) Multiple endocrine neoplasia type 2 syndromes may be associated with renal malformations. |
46. |
Farndon JR et al. (1986) Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. |
47. |
Marsh DJ et al. (2003) Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. |
48. |
Machens A et al. (2003) Early malignant progression of hereditary medullary thyroid cancer. |
49. |
Abu-Amero KK et al. (2006) Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome. |
50. |
Bongarzone I et al. (1994) Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. |
51. |
Takami H et al. (1996) Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. |
52. |
Burgess JR et al. (1997) Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. |
53. |
Pierotti MA et al. (1996) Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. |
55. |
Learoyd DL et al. (1998) RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. |
56. |
Sugg SL et al. (1998) Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. |
57. |
Canzian F et al. (1998) A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. |
58. |
Lesueur F et al. (1999) Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium. |
59. |
Trovato M et al. (1999) Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. |